Chemed Stock Forecast, Price & News

Chemed's stock was trading at $414.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHE stock has increased by 16.1% and is now trading at $480.63.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Chemed.

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) posted its earnings results on Wednesday, July, 29th. The company reported $4.41 earnings per share for the quarter, beating analysts' consensus estimates of $3.75 by $0.66. The company earned $502.20 million during the quarter, compared to analysts' expectations of $522.90 million. Chemed had a return on equity of 36.71% and a net margin of 12.99%. The firm's quarterly revenue was up 6.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.36 earnings per share.
View Chemed's earnings history.

Chemed announced a quarterly dividend on Thursday, August 6th. Shareholders of record on Monday, August 17th will be given a dividend of $0.34 per share on Friday, September 4th. This represents a $1.36 annualized dividend and a dividend yield of 0.28%. The ex-dividend date is Friday, August 14th. This is an increase from Chemed's previous quarterly dividend of $0.32.
View Chemed's dividend history.

Chemed issued an update on its FY20 earnings guidance on Wednesday, July, 29th. The company provided earnings per share guidance of $16.20-16.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.13.

3 Wall Street analysts have issued 1-year price targets for Chemed's shares. Their forecasts range from $490.00 to $535.00. On average, they expect Chemed's stock price to reach $520.00 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price.
View analysts' price targets for Chemed.

Chemed saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 125,100 shares, a decline of 31.6% from the August 15th total of 182,900 shares. Based on an average daily volume of 85,800 shares, the days-to-cover ratio is currently 1.5 days. Approximately 0.8% of the shares of the company are short sold.
View Chemed's Short Interest.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), AbbVie (ABBV), Abbott Laboratories (ABT), Costco Wholesale (COST), Home Depot (HD), Johnson & Johnson (JNJ), Boeing (BA), CVS Health (CVS), Verizon Communications (VZ) and Altria Group (MO).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (11.67%), Neuberger Berman Group LLC (3.98%), Riverbridge Partners LLC (2.12%), FMR LLC (2.11%), Bank of America Corp DE (1.31%) and Bank of New York Mellon Corp (1.26%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Vanguard Group Inc., Ninety One UK Ltd, FMR LLC, Canada Pension Plan Investment Board, Boston Trust Walden Corp, Riverbridge Partners LLC, and Neuberger Berman Group LLC. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, and Spencer S Lee.
View insider buying and selling activity for Chemed.

CHE stock was acquired by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, WFA of San Diego LLC, WFA of San Diego LLC, Trinity Street Asset Management LLP, Marshall Wace North America L.P., Bank of America Corp DE, Point72 Asset Management L.P., and Teacher Retirement System of Texas.
View insider buying and selling activity for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $480.63.

Chemed has a market capitalization of $7.65 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe.

The official website for Chemed is www.chemed.com.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.